Anna’s biggest mistake was not reducing the treasury shares in proportion with the outstanding. I told them that at the 2010 or so ASM in Toronto. TC was there. Big mistake. No need to complicate a biotech struggling to stay listed with an acquisition they can’t afford with a company (GMD) that had ownership that’s suspect. I supported it once they made that direction because it’s better than OTC. But it was a bad decision. It caused loss of Nasdaq. Bad moves by Anna.

Generex needs to keep their focus simple. Look at $GSLI. We have without a doubt a better vaccine vs. GP2. They kept it focused- all messaging on data and CEO presentations. A clean spin out. National listing. Complete focus on what is wanted in biotech.

NGIO is the winning avenue. Vaccine development. Covid and get the AE37/ Keytruda of 20 patients going. No MSO or whatever until then. Focus laser point. Show success in true human studies. Raise the pps. All and only vaccine. No money in Arizona. Jmho. Be a holding company when you can afford it. And that’s after a spin out of NGIO. Just my opinion.